Beam Therapeutics is pioneering the use of proprietary base-editing technology to develop powerful, uniquely precise genetic machines that rewrite genetic code, one letter at a time.
HPFH program achieves in vivo proof of concept of long term engraftment with >90% base editing maintained after 16 weeks Makassar program demonstrates…
Read MoreCAMBRIDGE, Mass. – November 21, 2019 – Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced that it will…
Read MoreMagazine honors the best employers in Massachusetts CAMBRIDGE – Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, has been named…
Read MoreCAMBRIDGE, Mass. – Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Graham Cooper to the…
Read MoreBeam Therapeutics’ board member Carole Ho among Endpoints’ 2019 list of “Twenty extraordinary women in biopharma R&D who worked their way to the top.”
Read MoreBeam Therapeutics’ Nicole Gaudelli among MIT Technology Review’s 35 Innovators Under 35 2019 “Pioneers” category.
Read MoreOur search for the next generation of scientific superstars had a stellar second year.
Read MoreDrugs based on gene editing are still in the earliest stages of development, but that’s not stopping new players looking at refining and improving…
Read More
The foundation of Beam’s work to develop precision genetic medicines is groundbreaking research coming out of the laboratories of our founders. Our base editing technologies were the subject of research published in Nature and Science in 2016 and 2017.